Advanced Filters
noise
Found 64,783 clinical trials
S SiWei Bao

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of SSGJ-707 comparing Pembrolizumab in subjects with advanced …

18 years of age All Phase 3

iMOVE: Virtual Reality PT Versus Traditional PT

This pragmatic, crossover, randomized controlled study evaluates the efficacy of virtual reality assisted physical therapy (VRPT) for improving the physical activity of hospitalized children as compared to traditional physical therapy. This is a pilot study that will be used to identify patient populations that can benefit the most from VRPT …

10 - 25 years of age All Phase N/A
A Agni Pantou, M.D

Autologous Platelet-Rich Plasma Intra-ovarian Infusion in Poor Responders

Autologous PRP intra ovarian infusion may improve ovarian response, patients' hormonal profile as well as fresh embryo transfer (ET)-ICSI cycles' outcome in patients presenting with Poor Ovarian Response (POR).

35 - 47 years of age Female Phase 2/3
S Sonia Michail, MD

The Use of Butyrate Therapy in Pediatric Ulcerative Colitis

Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.

7 - 21 years of age All Phase 1
M Melissa Mageno

Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of IBS-C

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and <18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.

12 - 17 years of age All Phase 3
M Mistue Aibe, MD

Conventional-therapy & FES-therapy In-Veritas Effects Study

This randomized clinical trial will primarily compare the effectiveness of conventional physiotherapy alone with combined conventional physiotherapy and FES-t along with task-specific training in terms of the improvement of the functional and neurological recovery of patients with persistent C5 palsy.

18 years of age All Phase N/A
E Elena Plante, PhD

The Effect of Prior Learning on Treatment of Morpheme Errors

This is a small-scale treatment study designed to determine which teaching methods result in the best learning. Treatment focuses on helping children with a developmental language disorder learn parts of grammar. Preschool children will receive assessments to determine whether they have a developmental language disorder and what parts of grammar …

4 - 6 years of age All Phase N/A
H Human and Animal Physiology

BCAAs, Muscle Protein Synthesis and Glucose Uptake

The present study aims to quantify the insulin sensitivity and the skeletal muscle protein synthetic response to consuming a test drink containing all amino acids or all amino acids except for BCAAs.

18 - 35 years of age All Phase N/A
Y Yanhua Ding, Doctor

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

The goal of this clinical trial is to compare the pharmacokinetic and safety similarity of QL2107 with Keytruda® marketed in China and the United States in healthy male volunteers. Participants will receive a single injection of QL2107/ Keytruda® (China)/Keytruda® (US).Researchers will compare pharmacokinetic, safety, and immunogenic similarities between the three …

18 - 50 years of age Male Phase 1
A Attie Stadler, MBChB, MPH

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

The PRESCIENT trial is a Phase IIc, open-label, randomized trial that will compare a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible pulmonary tuberculosis. Eligible participants will be randomized in a 1:1 ratio to BDQ, CFZ, PZA, and DLM (BCZD) or …

18 years of age All Phase 2

Simplify language using AI